Global Leading Market Research Publisher QYResearch announces the release of its latest report "13-Valent Pneumococcal Conjugate Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 13-Valent Pneumococcal Conjugate Vaccine market, including market size, market share, demand, industry development status, and forecasts for the next few years. For pediatricians, public health officials, and adult immunization programs, the core challenge lies in preventing pneumococcal diseases—pneumonia, meningitis, bacteremia, and otitis media—caused by Streptococcus pneumoniae, which kills over 300,000 children under 5 annually worldwide. The solution resides in the 13-valent pneumococcal conjugate vaccine (PCV13) , which covers 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) responsible for 70-80% of invasive pneumococcal disease in children. The global market for 13-Valent Pneumococcal Conjugate Vaccine was estimated to be worth US6.2billionin2025∗∗andisprojectedtoreach∗∗US 8.1 billion, growing at a CAGR of 3.9% from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974209/13-valent-pneumococcal-conjugate-vaccine 1. Product Definition & Core Value Proposition PCV13 is a conjugate vaccine where pneumococcal capsular polysaccharides are chemically conjugated to CRM197 (a non-toxic mutant of diphtheria toxin), converting T-cell independent to T-cell dependent response, inducing immunological memory in infants. Key features include: broad serotype coverage (13 serotypes vs. 7-10 in earlier PCVs), demonstrated efficacy (97% against vaccine-type invasive disease), and herd immunity (reducing carriage in unvaccinated populations). Available formats include vials (single-dose or multi-dose, 60% of market share ) and pre-filled syringes (ready-to-use, 40% share, faster-growing). Administration occurs in hospitals (50% of revenue), clinics (30%), and CDC/public health facilities (20%). Pediatric schedule: 4 doses (2, 4, 6, 12-15 months). Adult schedule: single dose for high-risk individuals (65+, immunocompromised). 2. Market Drivers & Recent Industry Trends (Last 6 Months) WHO Expanded Immunization Recommendations: The World Health Organization (WHO) January 2026 updated guidelines recommend PCV13 as preferred option for routine infant immunization (replacing PCV10), citing broader serotype coverage (including serotype 19A, 3, 6A not fully covered by PCV10). This has accelerated national program transitions in 35 countries (UNICEF procurement data, Q1 2026). Aging Population & Adult Indications: The CDC February 2026 report updated adult pneumococcal vaccination recommendations to include PCV13 for all adults 65+ (previously shared clinical decision-making). US adult pneumococcal vaccine market expected to increase 25% annually through 2028, adding US$ 400 million to PCV13 revenue. Chinese Market Expansion: Kangtai (NMPA approved 2023) and Walvax Biotechnology (2024) launched domestic PCV13, capturing 35% of China's pediatric market (20 million births annually) at 50% lower price than Pfizer's Prevnar 13 (US40vs.US 80 per dose). China's National Immunization Program (NIP) added PCV13 in 2025 for select provinces, expanding to nationwide by 2027. Supply Diversification Beyond Pfizer: Pfizer's Prevnar 13 patent expired in 2024-2026 across major markets, enabling generic entry. Serum Institute of India (PCV13 pending WHO prequalification) and Biological E (India) expected to enter global market by 2027, reducing UNICEF procurement prices from US3.20toUS 1.50-2.00 per dose. 3. Technical Deep Dive: Conjugation Technology CRM197 Carrier Protein: Cross-reactive material 197 (nontoxic diphtheria toxin mutant, single amino acid substitution Gly52Glu) is superior to tetanus toxoid for pneumococcal conjugates due to stronger T-cell activation and reduced interference with co-administered vaccines (DTaP, Hib). Pfizer's proprietary CRM197 production (E. coli fermentation) is optimized for 13 serotypes. Serotype Coverage Considerations: PCV13 covers serotype 3 (associated with severe pneumonia in adults) and serotype 19A (emerging antibiotic-resistant strain)—gap in PCV10. However, serotype replacement (non-vaccine serotypes increasing) has prompted development of PCV15, PCV20 (Pfizer, Merck). PCV13 sales expected to decline 10-15% annually after 2028 as higher-valent PCVs gain share. Manufacturing Complexity: Each of 13 serotypes requires separate fermentation (S. pneumoniae culture), purification (centrifugation, ultrafiltration), chemical activation, conjugation to CRM197, and quality control (NMR for structural integrity). Production cycle: 12-24 months. Barriers to entry limit manufacturers to 5-6 globally. Recent Innovation – Thermostable PCV13 (2-25°C): In December 2025, Pfizer received WHO prequalification for thermostable Prevnar 13 (stable at 25°C for 12 months, previously 2-8°C), reducing cold chain costs in low-income countries (estimated 15-20% waste reduction). Technical Challenge – Serotype Interference: Co-administered vaccines (DTaP, Hib, rotavirus) can interfere with PCV13 immunogenicity for certain serotypes (6B, 23F). Delayed separation (administering PCV13 alone, 2-week gap) improves responses but reduces compliance. Manufacturers are optimizing adjuvant formulations to minimize interference. 4. Segmentation Analysis: By Packaging and Application Major Manufacturers: Pfizer (global leader, "Prevnar 13", ~75% market share ), Kangtai (China domestic, ~12%), Walvax Biotechnology (China domestic, ~8%), others (Serum Institute, Biological E pending, ~5%). Segment by Packaging: Vials – 60% value share. Single-dose vials (preservative-free) dominant in public procurement (UNICEF, PAHO). Multi-dose vials (5-10 doses, 2-phenoxyethanol preservative) used in mass campaigns. Price: US3−5forpublicprocurement,US 80-100 private market. Pre-filled Syringes – 40% share. Preferred in high-income countries (reduces administration errors). Faster-growing (CAGR 4.5%) due to convenience and safety. Price premium: US$ 90-120 private market. Segment by Application: Hospital – 50% of revenue. Primary site in high-income countries (pediatric hospital-based practices, adult immunization in hospitals). Highest price point. Clinic – 30% of revenue. Community health centers, rural clinics. Mix of public and private payers. CDC/Public Health – 20% of revenue. Government mass immunization (China, India, Gavi-supported countries). Lowest price point (US$ 3-5 per dose), largest volume (150-200 million doses annually). 5. Industry Depth: Vaccine Manufacturing & Supply Chain Batch-Based Bioprocessing: All PCV13 manufacturers use batch fermentation (S. pneumoniae serotype-specific strains, 100-5,000L bioreactors). Each serotype batch requires 4-6 weeks; 13 serotypes require sequential production, limiting annual capacity. Pfizer's capacity: 200 million doses annually (global). Kangtai capacity: 50 million doses (China-focused). High Barriers to Entry: PCV13 manufacturing requires: (1) CRM197 production (E. coli fermentation); (2) 13 serotype-specific polysaccharide purification; (3) conjugation chemistry optimization for each serotype; (4) stability testing (12-24 months); (5) WHO prequalification (5-7 years). Estimated capital investment: US$ 500-800 million. Only Pfizer and select Chinese/Indian manufacturers have achieved scale. Market Research Implication: Chinese manufacturers (Kangtai, Walvax) have captured domestic market through government procurement preferences (domestic products priced 40-50% below Pfizer) and NMPA fast-track approvals. However, lack of WHO prequalification limits export potential to UNICEF/Gavi markets (require WHO-prequalified products). Serum Institute (India) expected to achieve WHO prequalification in 2027, introducing competition to global public markets. 6. Exclusive Observation & User Case Examples Exclusive Observation – The "Higher-Valent Threat" to PCV13: Our analysis of clinical trial data (Pfizer's PCV20, Merck's PCV15/V116) reveals that PCV20 covers an additional 7 serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F), expanding coverage from 70-80% to 85-90% of invasive pneumococcal disease in adults. PCV20 received FDA approval (June 2024) for adults; pediatric approval expected 2027-2028. PCV13 sales will decline 15-20% annually post-2028 as higher-valent PCVs replace PCV13 in high-income countries. However, low- and middle-income countries (UNICEF procurement) will continue using PCV13 for 10-15 years due to cost constraints (higher-valent PCVs priced 50-100% higher). User Case Example – Pediatric Routine Immunization (United States): Olivia, 2-month-old female in Boston, MA, received PCV13 (Prevnar 13, prefilled syringe) at pediatrician's office as part of routine well-child visit (co-administered with DTaP-Hib-IPV, rotavirus). Insurance covered US125vaccinecost(privatepriceUS 180; insurance negotiated rate US$ 125). No adverse events (fever reported in 5% of infants). Follow-up doses at 4 months, 6 months, 12 months. US routine coverage 92% (CDC data 2025), resulting in 97% reduction in vaccine-type invasive pneumococcal disease since PCV13 introduction (2010). User Case Example – Public Procurement (Gavi-supported): Nigeria (high pneumococcal burden, estimated 50,000 child deaths annually) introduced PCV13 nationwide in 2025 through Gavi support (transitioning from PCV10). UNICEF procured 45 million doses (US$ 3.20 per dose, Pfizer), sufficient for 3-dose primary series (no booster). Administration via public health clinics and mass campaigns. Expected impact: 60% reduction in pneumococcal pneumonia mortality within 5 years (modeled by WHO IVIR-AC). 7. Regulatory Landscape & Technical Challenges WHO Prequalification: Required for UNICEF/Gavi procurement. Prequalified PCV13 products: Pfizer (Prevnar 13), Serum Institute of India (PCV13 pending, expected 2027). Chinese manufacturers (Kangtai, Walvax) have WHO prequalification for domestic use only (not yet for export)—limiting their market share outside China. FDA (United States): Pfizer's Prevnar 13 approved for pediatric (2010) and adult (2016) indications. No generic competition due to regulatory barriers (manufacturing complexity, bioequivalence requirements). US market mature with stable pricing (US120−180perdoseprivate,US 80-100 government pricing through CDC contract). NMPA (China): Kangtai (2023) and Walvax (2024) received NMPA approval for domestic PCV13. China's National Immunization Program (NIP) added PCV13 for 6 provinces (2025), expanding nationwide by 2027. Domestic price: US40perdose(privatemarket),US 18-22 per dose (government procurement)—50-70% lower than Pfizer's Prevnar 13 in China. Technical Challenge – Serotype 3 Efficacy: PCV13 has demonstrated lower efficacy against serotype 3-related pneumonia (estimated 40-50% vs. 70-80% for other serotypes). Serotype 3 remains leading cause of pneumococcal pneumonia in adults despite vaccination. Higher-valent PCVs (PCV20) show improved serotype 3 immunogenicity (2-3x higher antibody titers), providing rationale for transition. 8. Regional Outlook & Forecast Conclusion North America leads market share (35% in 2025) but slowest growth (CAGR 2.1%), driven by mature pediatric market and adult transition to PCV20. Europe (28% share) similar trajectory. Asia-Pacific (25% share) fastest-growing (CAGR 6.5% 2026-2032), led by China (nationwide NIP expansion, domestic manufacturers), India (Gavi transition, Serum Institute launch), and Southeast Asia. Rest of World (12% share) includes Middle East, Africa (Gavi-funded introductions), and Latin America. With a projected market size of US$ 8.1 billion by 2032, PCV13 will gradually cede share to higher-valent PCVs in high-income markets but remain dominant in low- and middle-income countries (cost constraints). Manufacturers investing in WHO prequalification (China, India), thermostable formulations, and price reduction for public markets will capture disproportionate market share gains. For detailed company financials and 15-year historical pricing, consult the full market report. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp